Lucia Carril-Ajuria

5PUBLICATIONS
19CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 05, 2025
High Circulating IL-6/IL-8 Is Associated with Intratumoral Myeloid Contexture and Poor Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.

Lucía Carril-Ajuria, Ronan Flippot, Marie Naigeon

|Apr 17, 2024
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors.

Ronan Flippot, Marcus Teixeira, Macarena Rey-Cardenas

|May 31, 2022
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.

Lucia Carril-Ajuria, Aude Desnoyer, Maxime Meylan

|Mar 25, 2022
Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.

Ray Manneh, Mauricio Lema, Lucía Carril-Ajuria

|Jan 22, 2022
Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review.

Lucia Carril-Ajuria, Maria Cruz Martin-Soberón, Guillermo de Velasco

Pageof 1

Frequent Collaborators

2 joint publications

Catherine Sautes-Fridman

2 joint publications

Ronan Flippot

2 joint publications

Nathalie Chaput

1 joint publications

Linda Ibatá